NCT04326374View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency

PHASE3UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 30, 2019

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Growth Hormone DeficiencyEndocrine System DiseasesHormonesPituitary DiseasesPituitary Disease, Anterior
Interventions
DRUG

TransCon hGH

Once weekly subcutaneous injection

DRUG

daily hGH

Once daily subcutaneous injection

Trial Locations (1)

430030

RECRUITING

Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan

Sponsors

Collaborators (1)

Ascendis Pharma A/S
All Listed Sponsors
collaborator

Ascendis Pharma A/S

INDUSTRY

lead

Visen Pharmaceuticals (Shanghai) Co., Ltd.

INDUSTRY